Prospective Phase II Study on Skin Toxicity on Low-Dose Doxycycline in Metastatic Colorectal Cancer Patients During Cetuximab and Panitumumab Treatment
Patients with metastatic colorectal cancer treated with cetuximab or panitumumab usually
develop the skin toxicity which can impair patients' quality of life as well as limit the
treatment. We designed this trial to assess the effect of simplified protocol of pre-emptive
treatment on the observed skin toxicities during cetuximab and panitumumab treatment of
The study is a cohort observational, single center study which should result in estimation
of particular types of toxicities, especially occurence of more severe (grade 2 and 3) side
effects and assess the tolerance of doxycyline in the prolonged administration.
The observation in the study is biweekly and is continued up to 8 weeks.
Observational Model: Cohort, Time Perspective: Prospective
number of patients with a severe skin toxicity
Lucjan S Wyrwicz, MD,PhD
Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology
Poland: Ethics Committee